|2.12||-0.0100||-0.47%||Vol 1.11M||1Y Perf 105.83%|
|Sep 23rd, 2021 12:46 DELAYED|
|- -%||- -|
|Target Price||6.00||Analyst Rating||Strong Buy 1.00|
|Potential %||183.02||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Price Range Ratio 52W %||33.88||Earnings Rating||Strong Sell|
|Market Cap||309.48M||Earnings Date||13th Aug 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.05|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||2.36M|
|Avg. Monthly Volume||3.27M|
|Avg. Quarterly Volume||5.66M|
Citius Pharmaceuticals Inc. (NASDAQ: CTXR) stock closed at 2.13 per share at the end of the most recent trading day (a 5.97% change compared to the prior day closing price) with a volume of 3.02M shares and market capitalization of 309.48M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 10 people. Citius Pharmaceuticals Inc. CEO is Myron Z. Holubiak.
The one-year performance of Citius Pharmaceuticals Inc. stock is 105.83%, while year-to-date (YTD) performance is 108.82%. CTXR stock has a five-year performance of -77.46%. Its 52-week range is between 0.87 and 4.56, which gives CTXR stock a 52-week price range ratio of 33.88%
Citius Pharmaceuticals Inc. currently has a PE ratio of -6.70, a price-to-book (PB) ratio of 2.22, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -25.29%, a ROC of -28.43% and a ROE of -28.34%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Citius Pharmaceuticals Inc., there were 1 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.05 for the next earnings report. Citius Pharmaceuticals Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Citius Pharmaceuticals Inc. is Strong Buy (1), with a target price of $6, which is +183.02% compared to the current price. The earnings rating for Citius Pharmaceuticals Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Citius Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Citius Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 29.24, ATR14 : 0.13, CCI20 : 11.44, Chaikin Money Flow : 0.00, MACD : 0.01, Money Flow Index : 46.52, ROC : 1.43, RSI : 55.42, STOCH (14,3) : 55.88, STOCH RSI : 1.00, UO : 49.34, Williams %R : -44.12), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Citius Pharmaceuticals Inc. in the last 12-months were:
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
This could take some time, please wait.